The clinical trial, which enrolled 160 patients across the U.S., Europe, Canada, and Japan, sought to reduce urticaria activity scores over a 12-week period. Despite testing three distinct dose regimens against a placebo, the drug failed to demonstrate a significant clinical benefit. Consequently, Evommune has officially halted further development of the oral antagonist for this specific indication.

Chief Medical Officer Eugene Bauer maintained that the data confirmed the drug’s safety profile, suggesting the compound remains viable for other therapeutic areas. The company is now pivoting its focus toward upcoming readouts for atopic dermatitis, expected in the third quarter, and an ongoing Phase 2b trial evaluating the drug for migraine prophylaxis. The market reaction erased a significant portion of the stock's 47% year-to-date gains, leaving shares trading at $18.